USDCHF: USDCHF continues trade above its major support the 1.0000 level, further strength is envisaged. This view remains above the mentioned support despite its price hesitation. On the upside, resistance resides at the 1.0100 level where a break will clear
November 10, 2015
It is hard to believe it is already November here in 2015 and the holidays are fast approaching. This is especially true for this ex-New Yorker as it is still 85 degrees down here in sunny Miami – I don’t
Yielding a retirement-saving 14% with a rock solid business model and crystal clear cash flows, you may not find a better dividend paying stock in this market. And, as an added bonus this company’s profits will actually increase when the
Lockup Expiration: Report Update 2 Below in Chart 1 is an updated top ten list of sample/return period combinations using data for stocks with a post IPO lockup expiration date from January 2013 through mid-October 2015. Additionally, the top ten
Day after day, investors hear about “foreign currency impacts” on earnings… which are dutifully shrugged off by pandering protagonists on mainstream media – “if you just ignore the currency effect, everything is awesome.” Well the truth is – unless you have lived
Always of special interest, since obviously this firm caters virtually exclusively to the 1%.
It was noted Tuesday that the company’s stock fell due to a slowdown in orders for equipment needed to build more iPhone 6s. This was a drag on tech indexes and other sectors given the high weighting the stock has
The Chart of the Day belongs to Parr Petroleum (OTCQB:PARR). I found the diversified energy stock by using Barchart to sort the Russell 3000 Index stocks first for a Weighted Alpha of 50.00+ or more, then for technical buy signals of 80% or better , then
Chinese Industrial Production numbers The markets have a handful of announcements during the session, but we believe Wednesday will feature the Chinese Industrial Production numbers. With this being the case, the market should have more or less a “risk on,
Earlier last week I did an instablog post walking through why M&A activity was likely to remain robust in the pharma and biotech sectors. I also invited readers to submit their picks of firms within the industry that they thought would make
